These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 31807908)
1. Potential Active Targeting of Gatifloxacin to Macrophages by Means of Surface-Modified PLGA Microparticles Destined to Treat Tuberculosis. Marcianes P; Negro S; Barcia E; Montejo C; Fernández-Carballido A AAPS PharmSciTech; 2019 Dec; 21(1):15. PubMed ID: 31807908 [TBL] [Abstract][Full Text] [Related]
2. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Suarez S; O'Hara P; Kazantseva M; Newcomer CE; Hopfer R; McMurray DN; Hickey AJ Pharm Res; 2001 Sep; 18(9):1315-9. PubMed ID: 11683246 [TBL] [Abstract][Full Text] [Related]
4. Phospholipid-modified poly(lactide-co-glycolide) microparticles for tuning the interaction with alveolar macrophages: In vitro and in vivo assessment. Li J; Zheng H; Li X; Su J; Qin L; Sun Y; Guo C; Beck-Broichsitter M; Moehwald M; Chen L; Zhang Y; Mao S Eur J Pharm Biopharm; 2019 Oct; 143():70-79. PubMed ID: 31446045 [TBL] [Abstract][Full Text] [Related]
5. PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B. Shi S; Hickey AJ Pharm Res; 2010 Feb; 27(2):350-60. PubMed ID: 20024670 [TBL] [Abstract][Full Text] [Related]
6. Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis. Andreu V; Larrea A; Rodriguez-Fernandez P; Alfaro S; Gracia B; Lucía A; Usón L; Gomez AC; Mendoza G; Lacoma A; Dominguez J; Prat C; Sebastian V; Ainsa JA; Arruebo M Nanomedicine (Lond); 2019 Mar; 14(6):707-726. PubMed ID: 30734643 [TBL] [Abstract][Full Text] [Related]
8. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. O'Hara P; Hickey AJ Pharm Res; 2000 Aug; 17(8):955-61. PubMed ID: 11028941 [TBL] [Abstract][Full Text] [Related]
9. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Yang Y; Bajaj N; Xu P; Ohn K; Tsifansky MD; Yeo Y Biomaterials; 2009 Apr; 30(10):1947-53. PubMed ID: 19135245 [TBL] [Abstract][Full Text] [Related]
11. Poly(lactic- Maghrebi S; Joyce P; Jambhrunkar M; Thomas N; Prestidge CA ACS Appl Mater Interfaces; 2020 Feb; 12(7):8030-8039. PubMed ID: 32013379 [TBL] [Abstract][Full Text] [Related]
12. Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines. Wang C; Muttil P; Lu D; Beltran-Torres AA; Garcia-Contreras L; Hickey AJ AAPS J; 2009 Mar; 11(1):139-47. PubMed ID: 19277872 [TBL] [Abstract][Full Text] [Related]
13. HPMA-PLGA Based Nanoparticles for Effective In Vitro Delivery of Rifampicin. Rani S; Gothwal A; Pandey PK; Chauhan DS; Pachouri PK; Gupta UD; Gupta U Pharm Res; 2018 Dec; 36(1):19. PubMed ID: 30511238 [TBL] [Abstract][Full Text] [Related]
14. Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages. Tukulula M; Gouveia L; Paixao P; Hayeshi R; Naicker B; Dube A Pharm Res; 2018 Mar; 35(6):111. PubMed ID: 29600438 [TBL] [Abstract][Full Text] [Related]
15. Controlled release from coated polymer microparticles embedded in tissue-engineered scaffolds. Hu Y; Hollinger JO; Marra KG J Drug Target; 2001; 9(6):431-8. PubMed ID: 11822815 [TBL] [Abstract][Full Text] [Related]
16. Polyester microparticles as a vaccine delivery system for brucellosis: influence of the polymer on release, phagocytosis and toxicity. Murillo M; Gamazo C; Irache JM; Goñi MM J Drug Target; 2002 May; 10(3):211-9. PubMed ID: 12075822 [TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of biodegradable urea-loaded microparticles as an approach for transdermal delivery. Haddadi A; Farboud ES; Erfan M; Aboofazeli R J Microencapsul; 2006 Sep; 23(6):698-712. PubMed ID: 17118885 [TBL] [Abstract][Full Text] [Related]
18. Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defence peptide (HDP) in experimental tuberculosis. Sharma A; Vaghasiya K; Gupta P; Singh AK; Gupta UD; Verma RK J Control Release; 2020 Aug; 324():17-33. PubMed ID: 32418903 [TBL] [Abstract][Full Text] [Related]
19. Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization. Parumasivam T; Leung SS; Quan DH; Triccas JA; Britton WJ; Chan HK Eur J Pharm Sci; 2016 Jun; 88():1-11. PubMed ID: 27049049 [TBL] [Abstract][Full Text] [Related]
20. Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. Effect of Labrafil addition on release in vitro. Fernández-Carballido A; Herrero-Vanrell R; Molina-Martínez IT; Pastoriza P Int J Pharm; 2004 Jul; 279(1-2):33-41. PubMed ID: 15234792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]